Clinical trials: Epirubicin, open to volunteers
Breast Cancer, Neoadjuvant Therapy
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4).
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
- Trial name
- NCT07372079
- Testing
- QL1706 combined with Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neuroendocrine Cancer
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
This study is a single prospective, parallel, double-cohort, multicenter phase II clinical trial, aiming to evaluate the efficacy and safety of ivonescimab (AK112) combined with IP chemotherapy ± TACE in the first-line treatment…
- Trial name
- NCT07712094
- Testing
- AK112, Irinotecan, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Triple Negative Breast Cancer
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes…
- Trial name
- NCT04437160
- Testing
- Epirubicin or Pirarubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Triple Negative Breast Cancer (TNBC)
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer
- Conditions
- Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
- Trial name
- NCT06768931
- Testing
- Biolosion (oral probiotic compound preparation)
- Where
- 5 sites in China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
TNBC - Triple-Negative Breast Cancer
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for…
- Trial name
- NCT07256964
- Testing
- Toripalimab, PCb-EC, PCb
- Volunteers
- 216 people
- Sponsor
- Henan Cancer Hospital
TNBC - Triple-Negative Breast Cancer
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with…
- Trial name
- NCT05862064
- Testing
- epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Fudan University
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
This study is for patients with locally advanced sinonasal adenoid cystic carcinoma (SNACC), a rare and challenging cancer that tends to invade nerves and the skull base.
- Conditions
- Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin
- Trial name
- EIC-SNACC (NCT07320508)
- Testing
- Epirubicin (E)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Breast Cancer
A Study for the Neoadjuvant Treatment of Breast Cancer
Due to the unique advantages of albumin-bound paclitaxel, several studies in China and abroad have tried to use albumin-bound paclitaxel for neoadjuvant treatment of breast cancer up to now.
- Trial name
- NCT05420454
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 1,576 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Triple Negative Breast Cancer (TNBC), Early Setting
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
LESLIE is a multicentric randomized controlled trial in patients with triple negative breast cancer receiving neoadjuvant chemo/immunotherapy (NAT).
- Trial name
- LESLIE (NCT06831955)
- Testing
- Exercise Therapy, Fasting-Mimicking Diet, SOC
- Where
- 10 sites in Belgium
- Volunteers
- 356 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
- Trial name
- NCT04136782
- Testing
- Albumin-bound paclitaxel combined with carboplatin, Epirubicin combined with docetaxel
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) followed by nab-paclitaxel combined with toripalimab in patients with previously untreated…
- Trial name
- NCT06914440
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Toripalimab, Neoadjuvant Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Xijing Hospital
Hepatocellular Carcinoma, Transarterial Chemoembolization
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery.
- Trial name
- NCT07281664
- Testing
- Transarterial chemoembolization (TACE), bevacizumab and atezolizumab
- Volunteers
- 30 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
HR Positive/HER2 Low Breast Cancer
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
This study is a prospective, multi-cohort, multicenter, open-label exploratory clinical trial. The primary study objective is to evaluate the pathologic complete response (PCR) of treatment of HR+/HER2-low breast cancer with…
- Trial name
- NCT07383818
- Testing
- Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab, Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 111 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Breast Cancer
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is as sociated with shorter overall survival than other breast cancer subtypes, despite the use of curative-intent anthracycline- and taxane-based systemic chemotherapy.
- Trial name
- PRISM-TNBC (NCT06802757)
- Testing
- Posaconazole, Nab-paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Shandong Cancer Hospital and Institute
Triple Negative Breast Cancer
MicroRNA Profiles in Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups.
- Trial name
- TARMAC (NCT04771871)
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 42 people
- Sponsor
- University College Hospital, Ibadan
Triple Negative Breast Cancer
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin.
- Trial name
- TARMAC (NCT06291064)
- Testing
- Cyclophosphamide, Epirubicin, Docetaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Triple Negative Breast Cancer
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as…
- Trial name
- NCT04301739
- Testing
- HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- Volunteers
- 522 people
- Sponsor
- Shanghai Henlius Biotech
HER2-Negative Locally Advanced Breast Cancer
Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Adebrelimab Combined with Chemotherapy with or without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally…
- Trial name
- NCT06908668
- Testing
- Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy, Neoadjuvant Chemotherapy Combined with Immunotherapy
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TNBC, Triple Negative Breast Cancer
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
This study is a multicenter, single-arm, investigator-initiated Phase II clinical trial. Eligible patients with treatment-naive early or locally advanced triple-negative breast cancer (TNBC), clinically staged as Stage II-III…
- Trial name
- NCT06977542
- Testing
- Ivonescimab
- Volunteers
- 53 people
- Sponsor
- Fudan University
Breast Cancer
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer
- Trial name
- NCT06227117
- Testing
- Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.